United Therapeutics Stock (NASDAQ:UTHR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$295.22

52W Range

$266.98 - $417.82

50D Avg

$301.01

200D Avg

$336.90

Market Cap

$13.28B

Avg Vol (3M)

$551.47K

Beta

0.57

Div Yield

-

UTHR Company Profile


United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,305

IPO Date

Jun 17, 1999

Website

UTHR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Unituxin$238.70M$198.90M$182.90M
Remodulin$538.10M$494.80M$500.20M
Product and Service, Other$22.10M$11.80M$13.80M
Orenitram$434.30M$359.40M$325.10M
Adcirca$23.80M$28.90M-
Tyvaso$1.62B$1.23B$873.00M

Fiscal year ends in Dec 24 | Currency in USD

UTHR Financial Summary


Dec 24Dec 23Dec 22
Revenue$2.88B$2.33B$1.94B
Operating Income$1.38B$1.18B$979.70M
Net Income$1.20B$984.80M$727.30M
EBITDA$1.38B$1.39B$1.04B
Basic EPS$26.44$21.04$15.98
Diluted EPS$24.64$19.81$15.00

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25Apr 30, 25 | 9:00 AM
Q4 24Feb 26, 25 | 9:00 AM
Q3 24Oct 30, 24 | 9:00 AM

Peer Comparison


TickerCompany
JAZZJazz Pharmaceuticals plc
ALKSAlkermes plc
TECHBio-Techne Corporation
NBIXNeurocrine Biosciences, Inc.
LQDALiquidia Corporation
LEGNLegend Biotech Corporation
BMRNBioMarin Pharmaceutical Inc.
PCVXVaxcyte, Inc.